Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Erlotinib (Primary) ; Capecitabine; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Apr 2016 Planned primary completion date changed from 1 Apr 2014 to 1 Apr 2018 as reported by ClinicalTrials.gov.
- 04 Dec 2014 New trial record
- 15 Nov 2012 Planned end date changed from Apr 2013 to Apr 2014 as reported by ClinicalTrials.gov.